Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 7/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | PRCP | P42785 | 6/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719793 | 0.92 | KCNH2 (0.68) | HPGDSKCNH2PRCPNR1I2ABCB11 | |
| SCHEMBL14273503 | 0.87 | KCNH2 (0.74) | HPGDSKCNH2PRCPNR1I2ABCB11 | |
| SCHEMBL16269990 | 0.85 | KCNH2 (0.61) | HPGDSKCNH2PRCPNR1I2ABCB11 | |
| SCHEMBL12159679 | 0.85 | KCNH2 (0.61) | HPGDSKCNH2PRCPNR1I2ABCB11 | |
| SCHEMBL695432 | 0.84 | KCNH2 (0.67) | HPGDSKCNH2PRCPNR1I2ABCB11 | |
| SCHEMBL690397 | 0.84 | KCNH2 (0.71) | HPGDSKCNH2PRCPNR1I2ABCB11 | |
| SCHEMBL19548079 | 0.84 | KCNH2 (0.71) | HPGDSKCNH2PRCPNR1I2ABCB11 | |
| SCHEMBL692686 | 0.83 | KCNH2 (0.74) | HPGDSKCNH2PRCPNR1I2ABCB11 | |
| SCHEMBL16105833 | 0.82 | KCNH2 (0.67) | HPGDSKCNH2PRCPNR1I2ABCB11 | |
| SCHEMBL692685 | 0.82 | KCNH2 (0.70) | HPGDSKCNH2PRCPNR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | HPGDS 582/4885KCNH2 4523/4885PRCP 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.